Last reviewed by Daniel Gana, MSc, Dr. Abraham Benavides, MD, and Brent Ristow PhD, JD 1/10/2025

As the global anxiety epidemic grows, millions of people find themselves trapped in a cycle of prescription medications and debilitating side effects. From generalized anxiety disorder (GAD) to post-traumatic stress disorder (PTSD) and performance anxiety, mental health issues are at an all-time high. 

WHO data shows a 25% increase in anxiety disorders over the past decade, with the numbers rising significantly during the pandemic. With pharmaceutical treatments often falling short, people are desperate for non-invasive, sustainable, and safe solutions.

A Rising Tide of Anxiety and the Search for Hope

Anxiety is no longer a quiet, personal struggle, it’s a widespread epidemic affecting 1 in 5 adults in the U.S. alone​. For those living with anxiety, daily life can feel like an uphill battle filled with relentless worry, fear, and stress. Traditional pharmaceutical treatments like benzodiazepines and SSRIs, while useful for some, come with side effects that include vomiting, diarrhea, suicidal thoughts, heart rhythm changes, dependency, and withdrawal​.

People are in search of better options, and cannabis is proving to be a promising one. Once largely overlooked, cannabinoids like CBD, CBG, CBDA, and THCA are now at the forefront of research on anxiety management. In this article, we review the current state of research around the use of cannabis in treating anxiety, combining established research with cutting-edge studies set to change the future​.

Natural, Antianxiety Cannabis Components

Cannabis is a natural alternative to prescription medications that has gained significant attention for its anxiolytic properties. Once dismissed as a recreational drug, cannabis is now emerging as a powerful tool in the fight against anxiety. This is thanks to the therapeutic properties of cannabinoids, terpenes, and flavonoids like: 

These nonintoxicating cannabinoids are well-tolerated and effective, as shown in clinical studies, even in doses as high as hundreds of milligrams

Meanwhile, THC, the primary intoxicating component, has a much narrower window of anxiety relief. Less than 10 mg of THC delivered orally has been associated with paranoia and increased anxiety.

Cannabis and Anxiety: How It Works in the Body

The endocannabinoid system (ECS) is key in regulating stress responses and maintaining balance in the body. Cannabinoids, both those naturally produced in the body (like anandamide) and those from cannabis, bind to CB1 and CB2 receptors within the ECS to influence mood, anxiety, and emotional regulation​.

Cannabinoids like CBD and CBG primarily interact with CB2 receptors, associated with immune regulation, while THC interacts with CB1 receptors, responsible for psychoactive effects. 

However, the impact of these cannabinoids on anxiety can vary. For instance, while THC can sometimes worsen anxiety, CBD and CBG are known to reduce it by modulating serotonin receptors. CBD also increases levels of anandamide, a naturally feel-good endocannabinoid.

Cannabis may work on anxiety by employing one or more of the following mechanisms.

  • Modulation of Serotonin Receptors (5-HT1A and 5HT2A)

Cannabinoids like CBD bind to serotonin receptors including 5HT1A and 5HT2A, which are responsible for modulating anxiety. The interaction between CBD and these receptors enhance their activity to promote a calming effect. 

Terpenes such as linalool and limonene are also reported interacting with serotonin receptors to provide anxiolytic effects. Their presence in combination with cannabinoids like CBD may contribute to relaxation and stress reduction. 

Flavonoids like apigenin, found in hemp, support serotonin modulation by providing antianxiety and sedative effects. Together, these compounds create a synergistic effect, stabilizing serotonin levels and reducing symptoms of anxiety. This entourage effect ensures a more holistic approach to emotional well-being by harmonizing chemical interactions in the brain.

  • Regulation of Endocannabinoid System (ECS)

Cannabinoids such as CBD and THC interact with CB1 and CB2 receptors in the ECS, fine-tuning mood and stress responses. Terpenes like beta-caryophyllene, a CB2 agonist, complement this by reducing anxiety, inflammation, and promoting calmness. Flavonoids like quercetin work alongside these compounds, enhancing the antioxidant properties of the ECS and other pathways that support overall emotional balance.

  • Reduction of Amygdala Activity

CBD reduces hyperactivity in the amygdala, easing fear and anxiety responses. Terpenes like myrcene enhance these effects with their sedative properties, calming overactive brain regions. Flavonoids like kaempferol, known for their neuroprotective actions, further contribute by reducing oxidative stress in the amygdala. The combined action of cannabinoids, terpenes, and flavonoids helps diminish anxiety triggers, supporting a calmer emotional state and improved stress management.

  • Activation of GABA-A Receptors

Cannabinoids, particularly CBD, enhance the activity of GABA-A receptors, promoting a calming effect. Terpenes such as linalool increase the efficacy of this process by augmenting the sedative actions of GABA. Flavonoids like apigenin, which naturally bind to GABA receptors, amplify relaxation and mitigate symptoms of anxiety. This synergy ensures an optimized inhibitory neurotransmitter response, fostering tranquility and reducing hyperactivity in the brain.

  • Anti-inflammatory Effects

Cannabinoids like CBD and THC exhibit potent anti-inflammatory effects, which reduce neuroinflammation linked to anxiety. Terpenes like pinene and myrcene amplify these properties by targeting inflammatory pathways in the brain. Flavonoids such as catechins add to this effect by scavenging free radicals and protecting neural tissues. Together, these compounds create a neuroprotective shield, addressing root causes of mood disorders and promoting long-term emotional stability.

  • Enhancement of Neurogenesis

Cannabinoids promote neurogenesis in the hippocampus, fostering better mood regulation. Terpenes like limonene support this by increasing neurotrophic factors that aid neuron growth.

  • Desensitization of TRPV1 Receptors

Cannabinoids like CBD modulate TRPV1 receptors, reducing their sensitivity and calming stress responses. Terpenes such as myrcene add to this by suppressing inflammatory signals linked to TRPV1 activity.

  • Activation of Adenosine Receptors

CBD and other cannabinoids increase adenosine signaling, promoting antianxiety and calming effects. Terpenes such as terpinolene enhance this action by supporting adenosine pathways. Flavonoids like rutin further augment the calming effects by improving adenosine receptor function. This collective activity ensures a balanced and tranquil state, effectively reducing anxiety and enhancing overall mental well-being.

Cannabis & Anxiety Disorders

Generalized Anxiety Disorder (GAD)

One of the most common forms of anxiety, GAD is characterized by chronic, excessive worry, sometimes accompanied by physical symptoms like sweating or racing heartbeat, which can be triggered in specific contexts. 

Foundational studies on CBD show significant reductions in GAD symptoms. A 2011 study demonstrates that CBD reduced anxiety during public speaking, a major trigger for GAD. Similar results have been observed in research on CBG, showing it can reduce stress without causing intoxication​.

Post-Traumatic Stress Disorder (PTSD)

For those living with PTSD, intrusive memories, nightmares, and hypervigilance can make daily life challenging. CBD shows significant potential in reducing these symptoms by interacting with the brain’s amygdala, which governs emotional memory. 

Moreover, THCA, the non-psychoactive acid version of THC, is found to reduce stress, nausea, and inflammation without causing a high, making it a useful option for those sensitive to THC.

Performance Anxiety and Social Anxiety Disorder (SAD)

Performance anxiety and SAD are often linked to extreme fear of social interactions or public speaking. CBDA, with its strong affinity for serotonin receptors, is shown to effectively alleviate performance anxiety at even low doses​.

Why Whole Plant Extracts Are Key For Anxiety Relief

Research consistently supports the idea that whole-plant extracts provide more robust therapeutic effects due to the entourage effect. For anxiety, full-spectrum extracts containing CBD, CBG, CBDA, and THCA likely offer the most comprehensive relief.

Additionally, several terpenes like linalool (found in lavender) and myrcene also contribute to cannabis’s anxiety-relieving properties, working alongside cannabinoids to promote calm​ness.

For those struggling with anxiety, cannabis offers hope beyond conventional pharmaceuticals, which often come with harsh side effects. Cannabinoids like CBD, CBG, CBDA, and THCA provide natural, non-invasive alternatives that may help manage anxiety disorders. Paired with lifestyle changes like mindfulness and exercise, cannabis can offer fast, effective relief.

As research continues to develop, it’s clear that cannabis is more than just a recreational plant—it could represent the future of anxiety treatment. The combination of cannabinoids found in whole plant extracts might just be the key to overcoming the crippling effects of anxiety and living a more balanced, fear-free life.

References:

  1. A, M., Y, H., F, N., M, P., & F, K. (2024). Evaluating the potential effects of apigenin on memory, anxiety, and social interaction amelioration after social isolation stress. PubMed.pubmed.ncbi.nlm.nih.gov/39367711/
  2. Anxiety Disorders. (2017, December). NAMI.www.nami.org/about-mental-illness/mental-health-conditions/anxiety-disorders/
  3. Bakas, T., van Nieuwenhuijzen, P. S., Devenish, S. O., McGregor, I. S., Arnold, J. C., & Chebib, M. (2017). The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors. Pharmacological Research, 119, 358–370.doi.org/10.1016/j.phrs.2017.02.022
  4. Benavides, A., & Blesching, U. (2024, April 5). Anxiety and Panic Disorders – Cannabis THC: CBD Ratios. Cannakeys.cannakeys.com/thc-cbd-for-anxiety-and-panic-disorders/
  5. Benavides, A. (2022, January 24). Cannabinoids and the Endocannabinoid System: A Match Made in Heaven. Cannabis Central.www.veriheal.com/blog/cannabinoids-and-the-endocannabinoid-system-a-match-made-in-heaven/
  6. Benavides, A. (2024, August 4). All About Anandamide: Taking Cannabinoid Treatment to New Heights. Cannabis Central.www.veriheal.com/blog/what-is-anandamide/
  7. Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., Martín-Santos, R., Hallak, J. E. C., Zuardi, A. W., & Crippa, J. A. S. (2011). Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients. Neuropsychopharmacology, 36(6), 1219–1226.doi.org/10.1038/npp.2011.6
  8. Bernatoniene, J., & Kopustinskiene, D. M. (2018). The Role of Catechins in Cellular Responses to Oxidative Stress. Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry, 23(4), 965.doi.org/10.3390/molecules23040965
  9. Bilbao, A., & Spanagel, R. (2022). Medical cannabinoids: A pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Medicine, 20, 259.doi.org/10.1186/s12916-022-02459-1
  10. Bitencourt, R. M., & Takahashi, R. N. (2018). Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder: From Bench Research to Confirmation in Human Trials. Frontiers in Neuroscience, 12, 502.doi.org/10.3389/fnins.2018.00502
  11. Cannabinoid CBG reduces anxiety and stress in first human clinical trial. (2024, July 31). ScienceDaily.www.sciencedaily.com/releases/2024/07/240731141232.htm
  12. COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide. (2022, March 2). World Health Organization.www.who.int/news/item/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide
  13. Cuttler, C., Stueber, A., Cooper, Z. D., & Russo, E. (2024). Acute effects of cannabigerol on anxiety, stress, and mood: A double-blind, placebo-controlled, crossover, field trial. Scientific Reports, 14(1), 16163.doi.org/10.1038/s41598-024-66879-0
  14. Dougnon, G., & Ito, M. (2020). Inhalation Administration of the Bicyclic Ethers 1,8- and 1,4-cineole Prevent Anxiety and Depressive-Like Behaviours in Mice. Molecules, 25(8), Article 8.doi.org/10.3390/molecules25081884
  15. Gulluni, N., Re, T., Loiacono, I., Lanzo, G., Gori, L., Macchi, C., Epifani, F., Bragazzi, N., & Firenzuoli, F. (2018). Cannabis Essential Oil: A Preliminary Study for the Evaluation of the Brain Effects. Evidence-Based Complementary and Alternative Medicine : eCAM, 2018, 1709182.doi.org/10.1155/2018/1709182
  16. Han, K., Wang, J.-Y., Wang, P.-Y., & Peng, Y.-C.-H. (2024). Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis. Psychiatry Research, 339, 116049.doi.org/10.1016/j.psychres.2024.116049
  17. Hg, A.-F., Ewm, P., L, H., B, S. M., Fr, S. P., P, S.-L., Sr, G., Mr, V. D. S., Jr, G. da S. A., L, P., R, G., Rs, A., H, D. M. C., Lj, Q.-J., N, M., & Jss, Q. (2020). Limonene, a food additive, and its active metabolite perillyl alcohol improve regeneration and attenuate neuropathic pain after peripheral nerve injury: Evidence for IL-1β, TNF-α, GAP, NGF and ERK involvement. PubMed.pubmed.ncbi.nlm.nih.gov/32652504/
  18. Jansen, C., Shimoda, L. M. N., Kawakami, J. K., Ang, L., Bacani, A. J., Baker, J. D., Badowski, C., Speck, M., Stokes, A. J., Small-Howard, A. L., & Turner, H. (2019). Myrcene and terpene regulation of TRPV1. Channels, 13(1), 344–366.doi.org/10.1080/19336950.2019.1654347
  19. Jha, N. K., Sharma, C., Hashiesh, H. M., Arunachalam, S., Meeran, M. N., Javed, H., Patil, C. R., Goyal, S. N., & Ojha, S. (2021). β-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19. Frontiers in Pharmacology, 12, 590201.doi.org/10.3389/fphar.2021.590201
  20. Jiang, W., Zhang, Y., Xiao, L., Van Cleemput, J., Ji, S.-P., Bai, G., & Zhang, X. (2005). Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. Journal of Clinical Investigation, 115(11), 3104–3116.doi.org/10.1172/JCI25509
  21. Jin, S., Zhang, L., & Wang, L. (2023). Kaempferol, a potential neuroprotective agent in neurodegenerative diseases: From chemistry to medicine. Biomedicine & Pharmacotherapy, 165, 115215.doi.org/10.1016/j.biopha.2023.115215
  22. Kim, J., Choi, P., Park, Y.-T., Kim, T., Ham, J., & Kim, J.-C. (2023). The Cannabinoids, CBDA and THCA, Rescue Memory Deficits and Reduce Amyloid-Beta and Tau Pathology in an Alzheimer’s Disease-like Mouse Model. International Journal of Molecular Sciences, 24(7), 6827.doi.org/10.3390/ijms24076827
  23. Leonard, B. E., & Aricioglu, F. (2023). Cannabinoids and neuroinflammation: Therapeutic implications. Journal of Affective Disorders Reports, 12, 100463.doi.org/10.1016/j.jadr.2023.100463
  24. Louis-Gray, K., Tupal, S., & Premkumar, L. S. (2022). TRPV1: A Common Denominator Mediating Antinociceptive and Antiemetic Effects of Cannabinoids. International Journal of Molecular Sciences, 23(17), 10016.doi.org/10.3390/ijms231710016
  25. Maioli, C., Mattoteia, D., Amin, H. I. M., Minassi, A., & Caprioglio, D. (2022). Cannabinol: History, Syntheses, and Biological Profile of the Greatest “Minor” Cannabinoid. Plants, 11(21), 2896.doi.org/10.3390/plants11212896
  26. Milanos, S., Elsharif, S. A., Janzen, D., Buettner, A., & Villmann, C. (2017). Metabolic Products of Linalool and Modulation of GABAA Receptors. Frontiers in Chemistry, 5, 46.doi.org/10.3389/fchem.2017.00046
  27. Pertwee, R. G., Rock, E. M., Guenther, K., Limebeer, C. L., Stevenson, L. A., Haj, C., Smoum, R., Parker, L. A., & Mechoulam, R. (2018). Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5‐HT1A receptor‐mediated suppression of nausea and anxiety in rats. British Journal of Pharmacology, 175(1), 100–112.doi.org/10.1111/bph.14073
  28. Qi, W., Qi, W., Xiong, D., & Long, M. (2022). Quercetin: Its Antioxidant Mechanism, Antibacterial Properties and Potential Application in Prevention and Control of Toxipathy. Molecules, 27(19), 6545.doi.org/10.3390/molecules27196545
  29. Raymundi, A. M., da Silva, T. R., Sohn, J. M. B., Bertoglio, L. J., & Stern, C. A. (2020). Effects of ∆9-tetrahydrocannabinol on aversive memories and anxiety: A review from human studies. BMC Psychiatry, 20, 420.doi.org/10.1186/s12888-020-02813-8
  30. Russo, E. B., Cuttler, C., Cooper, Z. D., Stueber, A., Whiteley, V. L., & Sexton, M. (2022). Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms. Cannabis and Cannabinoid Research, 7(5), 706–716.doi.org/10.1089/can.2021.0058
  31. Sommano, S. R., Chittasupho, C., Ruksiriwanich, W., & Jantrawut, P. (2020). The Cannabis Terpenes. Molecules, 25(24), 5792.doi.org/10.3390/molecules25245792
  32. Surendran, S., Qassadi, F., Surendran, G., Lilley, D., & Heinrich, M. (2021). Myrcene—What Are the Potential Health Benefits of This Flavouring and Aroma Agent? Frontiers in Nutrition, 8, 699666.doi.org/10.3389/fnut.2021.699666
  33. Tm, S., S, P., & Cj, H. (2021). Contribution of the Adenosine 2A Receptor to Behavioral Effects of Tetrahydrocannabinol, Cannabidiol and PECS-101. PubMed.pubmed.ncbi.nlm.nih.gov/34500787/
  34. Wakshlag, J. J., Schwark, W. S., Deabold, K. A., Talsma, B. N., Cital, S., Lyubimov, A., Iqbal, A., & Zakharov, A. (2020). Pharmacokinetics of Cannabidiol, Cannabidiolic Acid, Δ9-Tetrahydrocannabinol, Tetrahydrocannabinolic Acid and Related Metabolites in Canine Serum After Dosing With Three Oral Forms of Hemp Extract. Frontiers in Veterinary Science, 7, 505. doi.org/10.3389/fvets.2020.00505
  35. Walsh, K. B., McKinney, A. E., & Holmes, A. E. (2021). Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses. Frontiers in Pharmacology, 12, 777804. doi.org/10.3389/fphar.2021.777804
  36. Wasowski, C., & Marder, M. (2012). Flavonoids as GABAA receptor ligands: The whole story? Journal of Experimental Pharmacology, 4, 9–24. doi.org/10.2147/JEP.S23105
  37. Weston-Green, K., Clunas, H., & Naranjo, C. J. (2021). A Review of the Potential Use of Pinene and Linalool as Terpene-Based Medicines for Brain Health: Discovering Novel Therapeutics in the Flavours and Fragrances of Cannabis. Frontiers in Psychiatry, 12, 583211. doi.org/10.3389/fpsyt.2021.583211

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team. Never miss a blog post or product release! Opt-out at any time.

You have Successfully Subscribed!